Knight Therapeutics Inc. (TSX:GUD)

Market Cap	584.97M
Revenue (ttm)	384.56M
Net Income (ttm)	383.00K
Shares Out	99.65M
EPS (ttm)	0.00
PE Ratio	1,527.34
Forward PE	209.64
Dividend	n/a
Ex-Dividend Date	n/a

Volume	51,464
Average Volume	46,186
Open	5.87
Previous Close	5.87
Day's Range	5.82 - 5.93
52-Week Range	5.09 - 6.55
Beta	0.13
RSI	37.65
Earnings Date	Nov 13, 2025

About Knight Therapeutics

Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2013
• Employees: 745
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: GUD